


Sub
Copy

Claim 33 (new). The method of Claim 31 wherein the ACAT inhibitor is 2,6-bis (1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamate.

Claim 34 (new). The method of Claim 10 wherein the plasma-triglyceride level-lowering agent is an ACAT inhibitor.

Claim 35 (new). The method of Claim 34 wherein the ACAT inhibitor is a compound of formula



wherein X and Y are oxygen, sulfur or (CR'R'')_n wherein n is 1 to 4; R is hydrogen, alkyl, or benzyl; and R¹ and R² are aryl and cycloalkyl.

Claim 36 (new). The method of Claim 35 wherein the ACAT inhibitor is 2,6-bis (1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamate.

REMARKS

Claims 1, 10, 21-24 and new claims 27-36 are all the claims remaining in the application.

The Examiner requires restriction of the present application under 35 USC § 121 "to a single disclosed species of a single specific composition comprising a specified individual active compound to be employed in the methods herein".

Applicants elect claims directed to a method of treating or preventing the onset of Alzheimer's Disease comprising administering to a human suffering from the disease an effective Alzheimer's Disease-alleviating or preventing amount of a plasma-triglyceride level-lowering agent. Furthermore, applicants elect ACAT inhibitors as a class of compounds and the species 2,6-bis(1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl] sulfamate.


Applicants have added new claims 27-36 to further define the above election. Support for new claims 27-36 is found in the specification at page 6, lines 16-20 and page 7,

lines 1-5. Thus, Claims 1, 10, 21-24, and new claims 27-36 read on the elected invention.

Applicants have cancelled the non-elected subject matter of Claims 2-9, 11-20, 25 and 26 without prejudice and reserve the right to file a divisional application to this subject matter.

Prosecution of the instant application on the merits is earnestly solicited.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Francis J. Tinney", written over a horizontal line.

Francis J. Tinney
Registration No. 33,069
Warner-Lambert Company
Patent Department
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-7295
Fax (734) 622-1553

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claims 2-~~9~~ have been cancelled.


Claims 11-~~20~~ have been cancelled.

Claims 25 and ~~26~~ have been cancelled.

Claim 27 (new). A method of treating or preventing the onset of Alzheimer's Disease comprising administering to a human suffering from the disease an effective Alzheimer's Disease-alleviating or preventing amount of an agent that interferes with cholesterol ester synthesis.

Claim 28 (new). The method of Claim 27 wherein the agent is an ACAT inhibitor.

Claim 29 (new). The method of Claim 28 wherein the ACAT inhibitor is a compound of formula




wherein X and Y are oxygen, sulfur or (CR'R'')_n wherein n is 1 to 4; R is hydrogen, alkyl, or benzyl; and R₁ and R₂ are aryl and cycloalkyl.

Claim 30 (new). The method of Claim 28 wherein the ACAT inhibitor is 2,6-bis (1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamate.

Claim 31 (new). The method of Claim 1 wherein the plasma-triglyceride level-lowering agent is an ACAT inhibitor.

Claim 32 (new). The method of Claim 31 wherein the ACAT inhibitor is a compound of formula




wherein X and Y are oxygen, sulfur or (CR'R'')_n wherein n is 1 to 4; R is hydrogen, alkyl, or benzyl; and R¹ and R² are aryl and cycloalkyl.

Claim 33 (new). The method of Claim 31 wherein the ACAT inhibitor is 2,6-bis (1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamate.

Claim 34 (new). The method of Claim 10 wherein the plasma-triglyceride level-lowering agent is an ACAT inhibitor.

Claim 35 (new). The method of Claim 34 wherein the ACAT inhibitor is a compound of formula



wherein X and Y are oxygen, sulfur or (CR'R'')_n wherein n is 1 to 4; R is hydrogen, alkyl, or benzyl; and R¹ and R² are aryl and cycloalkyl.

Claim 36 (new). The method of Claim 34 wherein the ACAT inhibitor is 2,6-bis (1-methylethyl)phenyl[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamate.